A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase

Cited by (830)

Items 201–300 of 830

1. Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status
   Paul M Hofman, Catherine Butori, Katia Havet, Véronique Hofman, Éric Selva, N. Guevara, José Santini, Ellen Van Obberghen‐Schilling · 2008 · British Journal of Cancer
2. Neudesin, a novel secreted protein with a unique primary structure and neurotrophic activity
   Ikuo Kimura, Masazumi Yoshioka, Morichika Konishi, Ayumi Miyake, Nobuyuki Itoh · 2004 · Journal of Neuroscience Research
3. Heparin stabilizes FGF-2 and modulates striatal precursor cell behavior in response to EGF
   Maeve A. Caldwell, Emmanuel Garcion, Melanie G. terBorg, Xiaoling He, Clive Niels Svendsen · 2004 · Experimental Neurology
4. Targeting the Epidermal Growth Factor Receptor With Tyrosine Kinase Inhibitors: Small Molecules, Big Hopes
   Jose M Baselga · 2002 · Journal of Clinical Oncology
5. Human papillomavirus type 18 E5 oncogene supports cell cycle progression and impairs epithelial differentiation by modulating growth factor receptor signalling during the virus life cycle
   Christopher W. Wasson, Ethan L. Morgan, Marietta Müller, Rebecca L. Ross, Margaret Hartley, Sally Roberts, Andrew Macdonald · 2017 · Oncotarget
6. Inhibitors of Src tyrosine kinase: the preparation and structure–activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines
   Yanong D. Wang, Karen Miller, Diane Harris Boschelli, Fei Ye, Biqi Wu, M. Brawner Floyd, Dennis W. Powell, Allan Wissner, Jennifer M. Weber, Frank Boschelli · 2000 · Bioorganic & Medicinal Chemistry Letters
7. Catalytically Active TYK2 Is Essential for Interferon-β-mediated Phosphorylation of STAT3 and Interferon-α Receptor-1 (IFNAR-1) but Not for Activation of Phosphoinositol 3-Kinase
   M.R. Sandhya Rani, Douglas W. Leaman, Yulong Han, Stewart Leung, Ed Croze, Eleanor N. Fish, Alan Wolfman, Richard M. Ransohoff · 1999 · Journal of Biological Chemistry
8. Retinoid regulation of heparin‐binding EGF‐like growth factor gene expression in human keratinocytes and skin*
   S. W. Stoll, James T. Elder · 1998 · Experimental Dermatology
9. Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR‐targeting agents to treat head and neck squamous cell carcinoma
   Hannah Zaryouh, Ines De Pauw, Hasan Baysal, Marc Peeters, Jan Baptist Vermorken, Filip Lardon, An Wouters · 2021 · Medicinal Research Reviews
10. The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: An overview
    James A. Crowell · 2005 · European Journal of Cancer
11. Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells.
    Fatih Mehmet Uckun, Rama Krishna Narla, X Jun, Tamer Zeren, Taracad K. Venkatachalam, Kevin G. Waddick, A Rostostev, Dorothea E. Myers · 1998 · PubMed
12. Tyrosine kinase inhibitors in cancer treatment (Part II)
    Peter M. Traxler · 1998 · Expert Opinion on Therapeutic Patents
13. Epidermal Growth Factor Induction of Apolipoprotein A-I Is Mediated by the Ras-MAP Kinase Cascade and Sp1
    Xi‐Long Zheng, Shuji Matsubara, Catherine T.M. Diao, Morley Donald Hollenberg, Norman C.W. Wong · 2001 · Journal of Biological Chemistry
14. Copper(II) Acetate/Oxygen‐Mediated Nucleophilic Addition and Intramolecular CH Activation/CN or CC Bond Formation: One‐Pot Synthesis of Benzimidazoles or Quinazolines
    Hua‐Feng He, Zhijing Wang, Weiliang Bao · 2010 · Advanced Synthesis & Catalysis
15. Small‐Molecule Kinase‐Inhibitors‐Loaded Boron Cluster as Hybrid Agents for Glioma‐Cell‐Targeting Therapy
    Marcos Couto, Ignacio Mastandrea, Mauricio Cabrera, Pablo Cabral, Francesç Teixidor, Hugo Cerecetto, Clara Viñas · 2017 · Chemistry - A European Journal
16. Differential Immediate Early Gene Expression in Conditional Hepatitis B Virus pX-transforming VersusNontransforming Hepatocyte Cell Lines
    Chi Tarn, Matthew L. Bilodeau, Ronald Loral Hullinger, OURANIA M. ANDRISANI · 1999 · Journal of Biological Chemistry
17. Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
    Cleo J. C. Connolly, James M. Hamby, Mel C. Schroeder, Mark R. Barvian, Gina H. Lu, Robert L. Panek, Aneesa M. Amar, Cindy Shen, Alan J. Kraker, David W. Fry et al. · 1997 · Bioorganic & Medicinal Chemistry Letters
18. Role of Ras in metal-induced EGF receptor signaling and NF-κB activation in human airway epithelial cells
    Weidong Wu, Ilona Jaspers, Wenli Zhang, Lee M. Graves, James M. Samet · 2002 · American Journal of Physiology-Lung Cellular and Molecular Physiology
19. Labeled EGFr‐TK irreversible inhibitor (ML03): In vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug
    Giuseppina Ortu, Iris Ben‐David, Yulia Rozen, Nanette M.T. Freedman, Roland Chisin, Alexander Levitzki, Eyal Mishani · 2002 · International Journal of Cancer
20. Calcium-Dependent Stimulation of Mitogen-Activated Protein Kinase Activity in A431 Cells by Low Doses of Ionizing Radiation
    Brian D. Kavanagh, Paul Dent, Rupert Schmidt‐Ullrich, Phylip Chen, Ross B. Mikkelsen · 1998 · Radiation Research
21. Metal Ion Signaling in Biomedicine
    Raphaël Rodriguez, Sebastian Müller, Ludovic Colombeau, Stéphanie Solier, Fabien Sindikubwabo, Tatiana Cañeque · 2025 · Chemical Reviews
22. Apoptosis occurs more frequently in metastatic foci than in primary lesions of human colorectal carcinomas: Analysis by terminal-deoxynucleotidyl-transferase-mediated dUTP-biotin nick end labeling
    Shigeru Tatebe, Masato Ishida, Noriko Kasagi, Shunichi Tsujitani, Nobuaki Kaibara, Hisao Ito · 1996 · International Journal of Cancer
23. Intersectin Activates Ras but Stimulates Transcription through an Independent Pathway Involving JNK
    Robert P. Mohney, Margaret Das, Trever Grant Bivona, Richard N. Hanes, Anthony G. Adams, Mark R. Philips, John P. O’Bryan · 2003 · Journal of Biological Chemistry
24. Brain Injury Expands the Numbers of Neural Stem Cells and Progenitors in the SVZ by Enhancing Their Responsiveness to EGF
    Dhivyaa Alagappan, Deborah A. Lazzarino, Ryan J. Felling, Murugabaskar Balan, Sergei V. Kotenko, Steven W. Levison · 2009 · ASN NEURO
25. A novel mechanism for anti‐EGFR antibody action involves chemokine‐mediated leukocyte infiltration
    Thomas Karl Hoffmann, Kerstin Schirlau, Enikö Sonkoly, Sven Brandau, Stephan Lang, Andor Pivarcsi, Vera Balz, Anja Müller, Bernhard Homey, Edwin Boelke et al. · 2009 · International Journal of Cancer
26. A catalyst- and solvent-free selective approach to biologically important quinazolines and benzo[g]quinazoline
    Vipan Kumar, Chander Mohan, Manish Gupta, Mohinder P. Mahajan · 2005 · Tetrahedron
27. Synthetic Strategies for 5- and 6-Membered Ring Azaheterocycles Facilitated by Iminyl Radicals
    John C. Walton · 2016 · Molecules
28. Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents
    Allan Wissner, M. Brawner Floyd, Sridhar K. Rabindran, Ramaswamy Nilakantan, Lee M. Greenberger, Ru Shen, Yufen Wang, Hwei‐Ru Tsou · 2002 · Bioorganic & Medicinal Chemistry Letters
29. Solid-phase synthesis of 1,3-dialkyl quinazoline-2,4-diones
    Brad O. Buckman, Raju Mohan · 1996 · Tetrahedron Letters
30. EGFR/HER-Targeted Therapeutics In Ovarian Cancer
    Jason A. Wilken, Tayf Badri, Sarah Cross, Rhoda Raji, Alessandro Davide Santin, Peter E. Schwartz, Adam J. Branscum, Andre T. Baron, Adam I Sakhitab, Nita J. Maihle · 2012 · Future Medicinal Chemistry
31. Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo
    Guan-Nan Zhang, Yunkai Zhang, Yi‐Jun Wang, Pranav Gupta, Charles R. Ashby, Saeed Alqahtani, Tongjin Deng, Susan Elaine Bates, Amal Kaddoumi, John N.D. Wurpel et al. · 2018 · Cancer Letters
32. CDK4 gene amplification in osteosarcoma: Reciprocal relationship withINK4A gene alterations and mapping of 12q13 amplicons
    Wei Guo, Fulvio Lonardo, Takafumi Ueda, Tonia K. Kim, Andrew G. Huvos, John H. Healey, Marc Ladanyi · 1999 · International Journal of Cancer
33. Consecutive Cycloaddition/SNAr/Reduction/Cyclization/Oxidation Sequences: A Copper-Catalyzed Multicomponent Synthesis of Fused N-Heterocycles
    Feng‐Cheng Jia, Xu Cheng, Zhi‐Wen Zhou, Qun Cai, Deng‐Kui Li, An‐Xin Wu · 2015 · Organic Letters
34. PET-Based Biodistribution and Radiation Dosimetry of Epidermal Growth Factor Receptor–Selective Tracer 11C-PD153035 in Humans
    Ningbo Liu, Minghuan Li, Xiaoyu Li, Xue Meng, Guoren Yang, Shuqiang Zhao, Yi Yang, Li Ma, Zheng Fu, Jinming Yu · 2009 · Journal of Nuclear Medicine
35. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice
    Mark W. Kunkel, Kenneth E. Hook, Curtis T. Howard, Sally A. Przybranowski, Billy J. Roberts, William L. Elliott, Wilbur R. Leopold · 1995 · Investigational New Drugs
36. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases
    William Alexander Denny · 2001 · Il Farmaco
37. EGF receptor crosstalks with cytokine receptors leading to the activation of c-Jun kinase in response to UV irradiation in human keratinocytes
    Y. Wan, Z.Q. Wang, John J. Voorhees, Gary J. Fisher · 2001 · Cellular Signalling
38. Protein-tyrosine Phosphatase-mediated Decrease of Epidermal Growth Factor and Platelet-derived Growth Factor Receptor Tyrosine Phosphorylation in High Cell Density Cultures
    Maria Sörby, Arne Östman · 1996 · Journal of Biological Chemistry
39. LOT1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein
    Abbas Abdollahi, Rudi Bao, Thomas C. Hamilton · 1999 · Oncogene
40. Copper-catalyzed cascade synthesis of benzimidazoquinazoline derivatives under mild condition
    Shan Xu, Juyou Lu, Hua Fu · 2011 · Chemical Communications
41. Nicotine‐induced phosphorylation of Akt through epidermal growth factor receptor and Src in PC12h cells
    Hitoshi Nakayama, Tadahiro Numakawa, Toshihiko Ikeuchi · 2002 · Journal of Neurochemistry
42. Keratinocyte Collagenase-1 Expression Requires an Epidermal Growth Factor Receptor Autocrine Mechanism
    Brian K. Pilcher, Jo Ann Dumin, Michael J. Schwartz, Bruce A. Mast, Gregory S. Schultz, William C. Parks, Howard G. Welgus · 1999 · Journal of Biological Chemistry
43. Extremely Tight Binding of Ruthenium Complex to Glycogen Synthase Kinase 3
    Gunes Ekin Atilla‐Gokcumen, Nicholas Pagano, Craig Nolan Streu, Jasna Maksimoska, P. Filippakopoulos, Stefan Knapp, Eric Meggers · 2008 · ChemBioChem
44. Gs Protein-coupled Receptor Agonists Induce Transactivation of the Epidermal Growth Factor Receptor in T84 Cells
    Lone S. Bertelsen, Kim Elaine Barrett, Stephen J. Keely · 2004 · Journal of Biological Chemistry
45. 1,2-Naphthoquinone activates vanilloid receptor 1 through increased protein tyrosine phosphorylation, leading to contraction of guinea pig trachea
    Shota Kikuno, Keiko Taguchi, Noriko Iwamoto, Shigeru Yamano, Arthur K. Cho, John R. Froines, Yoshito Kumagai · 2005 · Toxicology and Applied Pharmacology
46. Elevation of the epidermal growth factor receptor and dependent signaling in human papillomavirus-infected laryngeal papillomas.
    D Johnston, Harry Hall, Teresa P. DiLorenzo, Bettie M. Steinberg · 1999 · PubMed
47. Tyrphostins IV—Highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines
    Aviv Gazit, Jeffrey Chen, Harald App, Gerald McMahon, Peter Hirth, Irit Chen, Alexander Levitzki · 1996 · Bioorganic & Medicinal Chemistry
48. Targeting the epidermal growth factor receptor for therapy of carcinomas
    Donna E. Davies, Stephen G. Chamberlin · 1996 · Biochemical Pharmacology
49. Tyrosine Kinase Inhibitors in Preclinical Development
    Mark L. Levitt, Patrick P. Koty · 1999 · Investigational New Drugs
50. PI3K-AKT pathway negatively controls EGFR-dependent DNA-binding activity of Stat3 in glioblastoma multiforme cells
    Mrinal K. Ghosh, Pankaj Sharma, Phyllis C. Harbor, Shaik O. Rahaman, Saikh Jaharul Haque · 2005 · Oncogene
51. Pediatric Radiation Oncology
    Karen Jean Marcus, Daphne Adele Haas-Kogan · 2009 · Elsevier eBooks
52. Pyrimidines and their Benzo Derivatives
    Gordon W. Rewcastle · 2008 · Elsevier eBooks
53. Inhibitors of growth factor signalling.
    A. Wakeling · 2005 · Endocrine-Related Cancer
54. Endocytosis as a stabilizing mechanism for tissue homeostasis
    Miri Adler, Avi Mayo, Xu Zhou, Ruth A. Franklin, Jeremy B. Jacox, Ruslan M. Medzhitov, Uri S. Alon · 2018 · Proceedings of the National Academy of Sciences
55. EGF receptor function is required in late G1for cell cycle progression induced by bombesin and bradykinin
    Chintda Santiskulvong, James W. Sinnett‐Smith, Enrique Rozengurt · 2001 · American Journal of Physiology-Cell Physiology
56. A practical solid phase synthesis of quinazoline-2,4-diones
    Hui Shao, Marcus Colucci, Shaojing Tong, Hesheng Zhang, Arlindo L. Castelhano · 1998 · Tetrahedron Letters
57. A Structural Atlas of Kinases Inhibited by Clinically Approved Drugs
    Qi Wang, Julie Anne Zorn, John Kuriyan · 2014 · Methods in enzymology on CD-ROM/Methods in enzymology
58. Induced Autocrine Signaling through the Epidermal Growth Factor Receptor Contributes to the Response of Mammary Epithelial Cells to Tumor Necrosis Factor α
    Wan‐Nan U. Chen, Ronald L. Woodbury, Loel E. Kathmann, Lee K. Opresko, Richard C. Zangar, H. Steven Wiley, Brian D. Thrall · 2004 · Journal of Biological Chemistry
59. Control of tight junctional sealing: role of epidermal growth factor
    David Flores-Benítez, A Ruiz-Cabrera, Catalina Flores-Maldonado, Liora Shoshani, Marcelino Cereijido, Rubén Gerardo Contreras · 2006 · American Journal of Physiology-Renal Physiology
60. Human Homeobox HOXA7 Regulates KeratinocyteTransglutaminase Type 1 and Inhibits Differentiation
    Peter T. LaCelle, Renata R. Polakowska · 2001 · Journal of Biological Chemistry
61. Protein kinase inhibition: natural and synthetic variations on a theme
    Susan Serota Taylor, Elzbieta Radzio-Andzelm · 1997 · Current Opinion in Chemical Biology
62. Peptide YY Y1 receptor activates mitogen-activated protein kinase and proliferation in gut epithelial cells via the epidermal growth factor receptor
    Peter Mannon, Jennifer M. Mele · 2000 · Biochemical Journal
63. In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants
    Anna Fredriksson, Peter Johnström, Jan‐Olov Thorell, G Von Heijne, Moustapha Hassan, Staffan Eksborg, Per Kogner, Per Borgström, Martin Ingvar, Sharon Stone‐Elander · 1999 · Life Sciences
64. Organische Synthese und biologische Signaltransduktion
    Klaus Hinterding, Daniel Alonso-Díaz, Herbert Waldmann · 1998 · Angewandte Chemie
65. Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors
    Li Sun · 2000 · Drug Discovery Today
66. FT‐IR, FT‐Raman and DFT calculations of 3‐{[(4‐fluorophenyl)methylene]amino}‐2‐phenylquinazolin‐4(3H)‐one
    Chacko Yohannan Panicker, K.R. Ambujakshan, Hema Tresa Varghese, Samuel Mathew, Subarna Ganguli, Ashis Kumar Nanda, Christian Van Alsenoy · 2008 · Journal of Raman Spectroscopy
67. Tyrosine kinase inhibitors and gemcitabine: New treatment options in pancreatic cancer?
    Axel Kleespies, K.‐W. Jauch, Christiane J. Bruns · 2006 · Drug Resistance Updates
68. Egr-1 inhibits the expression of extracellular matrix genes in chondrocytes by TNFα-induced MEK/ERK signalling
    Jason S. Rockel, Suzanne M. Bernier, Andrew Leask · 2009 · Arthritis Research & Therapy
69. Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors
    Shuang Lü, Wei Zheng, Liyun Ji, Qun Luo, Xiang Hao, Xianchan Li, Fuyi Wang · 2012 · European Journal of Medicinal Chemistry
70. Comparison of Bioluminescent Kinase Assays Using Substrate Depletion and Product Formation
    Cordelle Tanega, Min Shen, Bryan T. Mott, Craig J. Thomas, Ryan MacArthur, James Inglese, Douglas S. Auld · 2009 · Assay and Drug Development Technologies
71. Acquisition of Inhibitor-Sensitive Protein Kinases through Protein Design
    Anthony C. Bishop, Kevan M. Shokat · 1999 · Pharmacology & Therapeutics
72. Design, synthesis and molecular docking of α,β-unsaturated cyclohexanone analogous of curcumin as potent EGFR inhibitors with antiproliferative activity
    Yunyun Xu, Yi Cao, Hailkuo Ma, Huan‐Qiu Li, Gui‐Zhen Ao · 2012 · Bioorganic & Medicinal Chemistry
73. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy.
    Mengfeng Li, Caisheng Ye, Chong Feng, Frank Riedel, Xiaoning Liu, Qing Zeng, Jennifer Rubin Grandis · 2002 · PubMed
74. A comparative QSAR analysis and molecular docking studies of quinazoline derivatives as tyrosine kinase (EGFR) inhibitors: A rational approach to anticancer drug design
    Malleshappa N. Noolvi, Harun Patel · 2011 · Journal of Saudi Chemical Society
75. Colored Petri net modeling and simulation of signal transduction pathways
    Dong‐Yup Lee, Ralf Zimmer, Sang Yup Lee, S PARK · 2005 · Metabolic Engineering
76. A Traceless Approach for the Parallel Solid-Phase Synthesis of 2-(Arylamino)quinazolinones
    Yongping Yu, John M. Ostresh, Richard A. Houghten · 2002 · The Journal of Organic Chemistry
77. TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation
    Michael D. Oberst, Stacey J Beberman, Zhao Liu, Juan Juan Yin, Yvona Ward, Kathleen Kelly · 2008 · BMC Cancer
78. Parallel Contractile Signal Transduction Pathways Activated by Receptors for Thrombin and Epidermal Growth Factor-Urogastrone in Guinea Pig Gastric Smooth Muscle: Blockade by Inhibitors of Mitogen-Activated Protein Kinase-Kinase and Phosphatidyl Inositol 3′-Kinase
    Xi‐Long Zheng, Bernard S. RENAUX, Morley Donald Hollenberg · 1998 · Journal of Pharmacology and Experimental Therapeutics
79. Catalytic Subunit of Cyclic AMP-Dependent Protein Kinase
    Susan Serota Taylor, Elzbieta Radzio-Andzelm, Madhusudan, Xiaodong Cheng, Lynn F. Ten Eyck, Narendra Narayana · 1999 · Pharmacology & Therapeutics
80. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib
    Jiabin An, Matthew B. Rettig · 2007 · Molecular Cancer Therapeutics
81. Direct Construction of Diverse Polyheterocycles Bearing Pyrrolidinediones via Rh(III)‐Catalyzed Cascade C−H Activation/Spirocyclization
    Shreedhar Devkota, Ha‐Jin Lee, Sung Hong Kim, Yong Rok Lee · 2019 · Advanced Synthesis & Catalysis
82. Signal Transduction Therapy with Rationally Designed Kinase Inhibitors
    Gÿorgý Kéri, László Őrfi, Dániel Erös, Bálint Hegymegi-Barakonyi, Csaba Szántai-Kis, Zoltan Horvath, Frigyes Wáczek, Marosfalvi Jeno, István Szabadkai, János Pató et al. · 2006 · Current Signal Transduction Therapy
83. A novel multi-component synthesis of 4-arylaminoquinazolines
    Majid Momahed Heravi, Samahe Sadjadi, Negar Mokhtari Haj, Hossein A. Oskooie, Rahim Hekmat Shoar, Fatemeh F. Bamoharram · 2008 · Tetrahedron Letters
84. Neurotrophic Actions of a Novel Molluscan Epidermal Growth Factor
    Petra M. Hermann, Ronald E. van Kesteren, Willem C. Wildering, Sherry D. Painter, John M. Reno, John S. Smith, Santosh Kumar, Wijnand P.M. Geraerts, Lowell H. Ericsson, August Benjamin Smit et al. · 2000 · Journal of Neuroscience
85. Combinatorial Synthesis of 3-Arylideneaminoquinazolin-4(1H)-one Derivatives Catalyzed by Iodine in Ionic Liquids
    Xiang‐Shan Wang, Jie Sheng, Lian Lu, Ke Yang, Yuling Li · 2011 · ACS Combinatorial Science
86. Synthesis and biological evaluation of aeroplysinin analogues: a new class of receptor tyrosine kinase inhibitors
    Klaus Hinterding, Axel Knebel, Peter Herrlich, Herbert Waldmann · 1998 · Bioorganic & Medicinal Chemistry
87. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
    Con Panousis, Veronika Rayzman, Terrance G. Johns, Christoph Renner, Zhong Liu, Gary A. Cartwright, F-T Lee, Dan Wang, Hui Kong Gan, D Cao et al. · 2005 · British Journal of Cancer
88. Oncogenic Ha-Ras-dependent Mitogen-activated Protein Kinase Activity Requires Signaling Through the Epidermal Growth Factor Receptor
    Mark Hamilton, Alan Wolfman · 1998 · Journal of Biological Chemistry
89. Synthesis of Quinazolines and Tetrahydroquinazolines: Copper‐Catalyzed Tandem Reactions of 2‐Bromobenzyl Bromides with Aldehydes and Aqueous Ammonia or Amines
    Xuesen Fan, Bin Li, Shenghai Guo, Yuanyuan Wang, Xinying Zhang · 2013 · Chemistry - An Asian Journal
90. EGFR signaling pathway and related-miRNAs in age-related diseases: the example of miR-221 and miR-222
    Ana Luísa Teixeira, Mónica Patrícia Gomes, Rui Medeiros · 2012 · Frontiers in Genetics
91. Hyperoxia induces Egr‐1 expression through activation of extracellular signal‐regulated kinase 1/2 pathway
    Nicole Jones, Faton H. Agani · 2003 · Journal of Cellular Physiology
92. Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts
    Patrick W. Vincent, Alex J. Bridges, Donald J. Dykes, David W. Fry, Wilber R. Leopold, Sandra J. Patmore, Billy J. Roberts, Steven Rose, Veronika Sherwood, Hairong Zhou et al. · 2000 · Cancer Chemotherapy and Pharmacology
93. Epithelial growth factor receptor interacting agents
    Jose M Baselga, Joan Albanell · 2002 · Hematology/Oncology Clinics of North America
94. The Mitogenic Potential of Heparin-Binding Epidermal Growth Factor in the Human Endometrium Is Mediated by the Epidermal Growth Factor Receptor and Is Modulated by Tumor Necrosis Factor-α
    Katya Chobotova, Mary-Elizabeth A. Muchmore, Janet G. Carver, Hyung Jin Yoo, Sanjiv Manek, William John Gullick, David H. Barlow, Helen J. Mardon · 2002 · The Journal of Clinical Endocrinology & Metabolism
95. Increasing β-catenin/Wnt3A activity levels drive mechanical strain-induced cell cycle progression through mitosis
    Benham-Pyle, Blair W, Sim, Joo Yong, Hart, Kevin C, Pruitt, Beth L, Nelson, William James · 2016 · eLife
96. Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline
    Deendyal Bhurta, Sandip Bibishan Bharate · 2021 · Medicinal Research Reviews
97. Pharmacophore modelling, molecular docking and virtual screening for EGFR (HER 1) tyrosine kinase inhibitors
    Amit Kumar Gupta, Shome Sankar Bhunia, Vishal M. Balaramnavar, Anil Kumar Saxena · 2011 · SAR and QSAR in environmental research
98. Inhibitors of serine/threonine kinases
    John C. Lee, Jerry L. Adams · 1995 · Current Opinion in Biotechnology
99. Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase
    Hyun Seung Ban, Taikou Usui, Wataru Nabeyama, Hidetoshi Morita, Kaori Fukuzawa, Hiroyuki Nakamura · 2009 · Organic & Biomolecular Chemistry
100. The preparation and sar of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: Inhibitors of p56lck and EGF-R tyrosine kinase activity
     Michael R. Myers, Natalie N. Setzer, Alfred P. Spada, Allison L. Zulli, Chin-Yi Jenny Hsu, Asher Zilberstein, Susan E. Johnson, Linda E. Hook, Mary V. Jacoski · 1997 · Bioorganic & Medicinal Chemistry Letters